You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameBopindolol
Accession NumberDB08807
TypeSmall Molecule
GroupsApproved
DescriptionBopindolol (INN) is a beta blocker. It is an ester which acts as a prodrug for "pindolol":http://drugbank.ca/drugs/DB00960.
Structure
Thumb
Synonyms
Sandonorm
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
SandonormNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIKT304VZO57
CAS number62658-63-3
WeightAverage: 380.48
Monoisotopic: 380.209992772
Chemical FormulaC23H28N2O3
InChI KeyUUOJIACWOAYWEZ-UHFFFAOYSA-N
InChI
InChI=1S/C23H28N2O3/c1-16-13-19-20(25-16)11-8-12-21(19)27-15-18(14-24-23(2,3)4)28-22(26)17-9-6-5-7-10-17/h5-13,18,24-25H,14-15H2,1-4H3
IUPAC Name
1-(tert-butylamino)-3-[(2-methyl-1H-indol-4-yl)oxy]propan-2-yl benzoate
SMILES
CC1=CC2=C(N1)C=CC=C2OCC(CNC(C)(C)C)OC(=O)C1=CC=CC=C1
Pharmacology
IndicationFor the management of hypertension, edema, ventricular tachycardias, and atrial fibrillation.
Structured Indications Not Available
PharmacodynamicsBopindolol is a prodrug of pindolol. Pindolol is a non-selective beta-adrenergic antagonist (beta-blocker) which possesses intrinsic sympathomimetic activity (ISA) in therapeutic dosage ranges but does not possess quinidine-like membrane stabilizing activity. Pindolol impairs AV node conduction and decreases sinus rate and may also increase plasma triglycerides and decrease HDL-cholesterol levels. Pindolol is nonpolar and hydrophobic, with low to moderate lipid solubility. Pindolol has little to no intrinsic sympathomimetic activity and, unlike some other beta-adrenergic blocking agents, pindolol has little direct myocardial depressant activity and does not have an anesthetic-like membrane-stabilizing action.
Mechanism of actionBopindolol (as pindolol) non-selectively blocks beta-1 adrenergic receptors mainly in the heart, inhibiting the effects of epinephrine and norepinephrine resulting in a decrease in heart rate and blood pressure. By binding beta-2 receptors in the juxtaglomerular apparatus, Pindolol inhibits the production of renin, thereby inhibiting angiotensin II and aldosterone production and therefore inhibits the vasoconstriction and water retention due to angiotensin II and aldosterone, respectively.
TargetKindPharmacological actionActionsOrganismUniProt ID
Beta-1 adrenergic receptorProteinyes
partial agonist
HumanP08588 details
Beta-2 adrenergic receptorProteinunknown
partial agonist
HumanP07550 details
5-hydroxytryptamine receptor 1AProteinunknownNot AvailableHumanP08908 details
5-hydroxytryptamine receptor 1BProteinunknownNot AvailableHumanP28222 details
Beta-3 adrenergic receptorProteinunknownNot AvailableHumanP13945 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Bopindolol Action PathwayDrug actionSMP00657
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Bopindolol.Experimental
4-Methoxyamphetamine4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Bopindolol.Experimental, Illicit
AceclofenacAceclofenac may decrease the antihypertensive activities of Bopindolol.Approved
AcepromazineAcepromazine may increase the hypotensive activities of Bopindolol.Approved, Vet Approved
AceprometazineAceprometazine may increase the hypotensive activities of Bopindolol.Approved
AcetohexamideBopindolol may increase the hypoglycemic activities of Acetohexamide.Withdrawn
AcetovanilloneAcetovanillone may decrease the antihypertensive activities of Bopindolol.Investigational
AcetylcholineThe risk or severity of adverse effects can be increased when Bopindolol is combined with Acetylcholine.Approved
AcetyldigitoxinBopindolol may increase the bradycardic activities of Acetyldigitoxin.Approved
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Bopindolol.Approved, Vet Approved
AdapaleneAdapalene may decrease the antihypertensive activities of Bopindolol.Approved
AgmatineAgmatine may increase the atrioventricular blocking (AV block) activities of Bopindolol.Experimental, Investigational
AlfentanilAlfentanil may increase the bradycardic activities of Bopindolol.Approved, Illicit
AlfuzosinBopindolol may increase the orthostatic hypotensive activities of Alfuzosin.Approved, Investigational
AlimemazineAlimemazine may increase the hypotensive activities of Bopindolol.Approved, Vet Approved
AmbenoniumAmbenonium may increase the bradycardic activities of Bopindolol.Approved
Ambroxol acefyllinateBopindolol may decrease the bronchodilatory activities of Ambroxol acefyllinate.Experimental
AminophyllineBopindolol may decrease the bronchodilatory activities of Aminophylline.Approved
AmiodaroneAmiodarone may increase the bradycardic activities of Bopindolol.Approved, Investigational
AmobarbitalThe serum concentration of Bopindolol can be decreased when it is combined with Amobarbital.Approved, Illicit
AmodiaquineThe metabolism of Bopindolol can be decreased when combined with Amodiaquine.Approved
AnisodamineAnisodamine may decrease the antihypertensive activities of Bopindolol.Investigational
AntipyrineAntipyrine may decrease the antihypertensive activities of Bopindolol.Approved
AnvirzelBopindolol may increase the bradycardic activities of Anvirzel.Investigational
ApomorphineApomorphine may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved, Investigational
ApremilastApremilast may decrease the antihypertensive activities of Bopindolol.Approved, Investigational
ArbutamineBopindolol may decrease the bronchodilatory activities of Arbutamine.Approved
ArecolineThe risk or severity of adverse effects can be increased when Bopindolol is combined with Arecoline.Experimental
ArformoterolBopindolol may decrease the bronchodilatory activities of Arformoterol.Approved, Investigational
AzapropazoneAzapropazone may decrease the antihypertensive activities of Bopindolol.Withdrawn
AzelastineAzelastine may decrease the antihypertensive activities of Bopindolol.Approved
BalsalazideBalsalazide may decrease the antihypertensive activities of Bopindolol.Approved, Investigational
BambuterolBopindolol may decrease the bronchodilatory activities of Bambuterol.Approved
BarbexacloneThe serum concentration of Bopindolol can be decreased when it is combined with Barbexaclone.Experimental
BarbitalThe serum concentration of Bopindolol can be decreased when it is combined with Barbital.Illicit
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Bopindolol.Withdrawn
BenzphetamineBenzphetamine may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved, Illicit
BethanecholThe risk or severity of adverse effects can be increased when Bopindolol is combined with Bethanechol.Approved
BethanidineBethanidine may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved
Betulinic AcidBetulinic Acid may decrease the antihypertensive activities of Bopindolol.Investigational
BL-1020BL-1020 may increase the hypotensive activities of Bopindolol.Investigational
BrimonidineBrimonidine may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved
BromfenacBromfenac may decrease the antihypertensive activities of Bopindolol.Approved
BromocriptineBromocriptine may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved, Investigational
BucillamineBucillamine may decrease the antihypertensive activities of Bopindolol.Investigational
BucindololBopindolol may increase the orthostatic hypotensive activities of Bucindolol.Investigational
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Bopindolol.Approved, Investigational
CabergolineBopindolol may increase the vasoconstricting activities of Cabergoline.Approved
CarbacholThe risk or severity of adverse effects can be increased when Bopindolol is combined with Carbachol.Approved
CarprofenCarprofen may decrease the antihypertensive activities of Bopindolol.Approved, Vet Approved, Withdrawn
CarvedilolBopindolol may increase the orthostatic hypotensive activities of Carvedilol.Approved, Investigational
CastanospermineCastanospermine may decrease the antihypertensive activities of Bopindolol.Experimental
CelecoxibCelecoxib may decrease the antihypertensive activities of Bopindolol.Approved, Investigational
CeliprololBopindolol may decrease the bronchodilatory activities of Celiprolol.Approved, Investigational
CevimelineThe risk or severity of adverse effects can be increased when Bopindolol is combined with Cevimeline.Approved
ChloroquineThe metabolism of Bopindolol can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorpromazineChlorpromazine may increase the hypotensive activities of Bopindolol.Approved, Vet Approved
ChlorpropamideBopindolol may increase the hypoglycemic activities of Chlorpropamide.Approved
ClenbuterolBopindolol may decrease the bronchodilatory activities of Clenbuterol.Approved, Vet Approved
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved
ClonixinClonixin may decrease the antihypertensive activities of Bopindolol.Approved
CoumaphosCoumaphos may increase the bradycardic activities of Bopindolol.Vet Approved
CurcuminCurcumin may decrease the antihypertensive activities of Bopindolol.Investigational
D-LimoneneD-Limonene may decrease the antihypertensive activities of Bopindolol.Investigational
DapoxetineThe serum concentration of Bopindolol can be increased when it is combined with Dapoxetine.Investigational
DecamethoniumDecamethonium may increase the bradycardic activities of Bopindolol.Approved
DemecariumDemecarium may increase the bradycardic activities of Bopindolol.Approved
DeslanosideBopindolol may increase the bradycardic activities of Deslanoside.Approved
DesvenlafaxineThe serum concentration of Bopindolol can be increased when it is combined with Desvenlafaxine.Approved
DexmedetomidineDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved, Vet Approved
DichlorvosDichlorvos may increase the bradycardic activities of Bopindolol.Vet Approved
DiclofenacDiclofenac may decrease the antihypertensive activities of Bopindolol.Approved, Vet Approved
DiflunisalDiflunisal may decrease the antihypertensive activities of Bopindolol.Approved
DigitoxinBopindolol may increase the bradycardic activities of Digitoxin.Approved
DigoxinBopindolol may increase the bradycardic activities of Digoxin.Approved
DihydroergotamineDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved
DiltiazemDiltiazem may increase the hypotensive activities of Bopindolol.Approved
DipivefrinBopindolol may decrease the bronchodilatory activities of Dipivefrin.Approved
DipyridamoleDipyridamole may increase the bradycardic activities of Bopindolol.Approved
DisopyramideDisopyramide may increase the bradycardic activities of Bopindolol.Approved
DobutamineBopindolol may decrease the bronchodilatory activities of Dobutamine.Approved
DonepezilDonepezil may increase the bradycardic activities of Bopindolol.Approved
DoxazosinBopindolol may increase the orthostatic hypotensive activities of Doxazosin.Approved
DronedaroneDronedarone may increase the bradycardic activities of Bopindolol.Approved
DroxicamDroxicam may decrease the antihypertensive activities of Bopindolol.Approved
DroxidopaBopindolol may decrease the bronchodilatory activities of Droxidopa.Approved, Investigational
DuloxetineThe serum concentration of Bopindolol can be increased when it is combined with Duloxetine.Approved
DuvelisibDuvelisib may decrease the antihypertensive activities of Bopindolol.Investigational
DyphyllineBopindolol may decrease the bronchodilatory activities of Dyphylline.Approved
E6201E6201 may decrease the antihypertensive activities of Bopindolol.Investigational
EbselenEbselen may decrease the antihypertensive activities of Bopindolol.Investigational
EchothiophateEchothiophate may increase the bradycardic activities of Bopindolol.Approved
EdrophoniumEdrophonium may increase the bradycardic activities of Bopindolol.Approved
EphedraBopindolol may decrease the bronchodilatory activities of Ephedra.Approved, Nutraceutical, Withdrawn
EPIBATIDINEThe risk or severity of adverse effects can be increased when Bopindolol is combined with EPIBATIDINE.Experimental
EpinephrineBopindolol may decrease the bronchodilatory activities of Epinephrine.Approved, Vet Approved
EpirizoleEpirizole may decrease the antihypertensive activities of Bopindolol.Approved
Ergoloid mesylateBopindolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
ErgonovineBopindolol may increase the vasoconstricting activities of Ergonovine.Approved
ErgotamineErgotamine may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved
EtanerceptEtanercept may decrease the antihypertensive activities of Bopindolol.Approved, Investigational
EtodolacEtodolac may decrease the antihypertensive activities of Bopindolol.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the antihypertensive activities of Bopindolol.Approved
EtomidateEtomidate may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved
EtoperidoneThe serum concentration of Bopindolol can be increased when it is combined with Etoperidone.Approved
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Bopindolol.Approved, Investigational
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Bopindolol.Approved
exisulindexisulind may decrease the antihypertensive activities of Bopindolol.Investigational
FenbufenFenbufen may decrease the antihypertensive activities of Bopindolol.Approved
FenoprofenFenoprofen may decrease the antihypertensive activities of Bopindolol.Approved
FenoterolBopindolol may decrease the bronchodilatory activities of Fenoterol.Approved
FentanylFentanyl may increase the bradycardic activities of Bopindolol.Approved, Illicit, Investigational, Vet Approved
FenthionFenthion may increase the bradycardic activities of Bopindolol.Vet Approved
FingolimodBopindolol may increase the bradycardic activities of Fingolimod.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Bopindolol.Approved, Withdrawn
FlunixinFlunixin may decrease the antihypertensive activities of Bopindolol.Vet Approved
FluoxetineThe serum concentration of Bopindolol can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FluphenazineFluphenazine may increase the hypotensive activities of Bopindolol.Approved
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Bopindolol.Approved, Investigational
FormoterolBopindolol may decrease the bronchodilatory activities of Formoterol.Approved, Investigational
GalantamineGalantamine may increase the bradycardic activities of Bopindolol.Approved
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Bopindolol.Approved
Ginkgo bilobaGinkgo biloba may increase the bradycardic activities of Bopindolol.Approved, Nutraceutical
GlibornurideBopindolol may increase the hypoglycemic activities of Glibornuride.Withdrawn
GliclazideBopindolol may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideBopindolol may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideBopindolol may increase the hypoglycemic activities of Glipizide.Approved
GliquidoneBopindolol may increase the hypoglycemic activities of Gliquidone.Approved
GlisoxepideBopindolol may increase the hypoglycemic activities of Glisoxepide.Approved
GlyburideBopindolol may increase the hypoglycemic activities of Glyburide.Approved
GTS-21The risk or severity of adverse effects can be increased when Bopindolol is combined with GTS-21.Investigational
GuanabenzGuanabenz may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved
GuanfacineGuanfacine may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved, Investigational
HexobarbitalThe serum concentration of Bopindolol can be decreased when it is combined with Hexobarbital.Approved
HigenamineHigenamine may decrease the antihypertensive activities of Bopindolol.Investigational
HMPL-004HMPL-004 may decrease the antihypertensive activities of Bopindolol.Investigational
Huperzine AHuperzine A may increase the bradycardic activities of Bopindolol.Investigational
HydroxychloroquineThe metabolism of Bopindolol can be decreased when combined with Hydroxychloroquine.Approved
IbuprofenIbuprofen may decrease the antihypertensive activities of Bopindolol.Approved
IbuproxamIbuproxam may decrease the antihypertensive activities of Bopindolol.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Bopindolol.Approved
IndacaterolBopindolol may decrease the bronchodilatory activities of Indacaterol.Approved
IndalpineThe serum concentration of Bopindolol can be increased when it is combined with Indalpine.Investigational, Withdrawn
IndomethacinIndomethacin may decrease the antihypertensive activities of Bopindolol.Approved, Investigational
IndoprofenIndoprofen may decrease the antihypertensive activities of Bopindolol.Withdrawn
IndoraminBopindolol may increase the orthostatic hypotensive activities of Indoramin.Withdrawn
Insulin PorkBopindolol may increase the hypoglycemic activities of Insulin Pork.Approved
IsoetarineBopindolol may decrease the bronchodilatory activities of Isoetarine.Approved
IsoflurophateIsoflurophate may increase the bradycardic activities of Bopindolol.Approved, Withdrawn
IsoprenalineBopindolol may decrease the bronchodilatory activities of Isoprenaline.Approved
IsoxicamIsoxicam may decrease the antihypertensive activities of Bopindolol.Withdrawn
KebuzoneKebuzone may decrease the antihypertensive activities of Bopindolol.Experimental
KetoprofenKetoprofen may decrease the antihypertensive activities of Bopindolol.Approved, Vet Approved
KetorolacKetorolac may decrease the antihypertensive activities of Bopindolol.Approved
LabetalolBopindolol may increase the orthostatic hypotensive activities of Labetalol.Approved
LeflunomideLeflunomide may decrease the antihypertensive activities of Bopindolol.Approved, Investigational
LevomilnacipranThe serum concentration of Bopindolol can be increased when it is combined with Levomilnacipran.Approved
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Bopindolol.Approved, Vet Approved
LisofyllineLisofylline may decrease the antihypertensive activities of Bopindolol.Investigational
LobelineThe risk or severity of adverse effects can be increased when Bopindolol is combined with Lobeline.Investigational
LofexidineLofexidine may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved, Investigational
LornoxicamLornoxicam may decrease the antihypertensive activities of Bopindolol.Approved
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Bopindolol.Approved
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Bopindolol.Approved, Investigational
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Bopindolol.Approved
MalathionMalathion may increase the bradycardic activities of Bopindolol.Approved, Investigational
MasoprocolMasoprocol may decrease the antihypertensive activities of Bopindolol.Approved
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Bopindolol.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Bopindolol.Approved
MefloquineMefloquine may increase the bradycardic activities of Bopindolol.Approved
MeloxicamMeloxicam may decrease the antihypertensive activities of Bopindolol.Approved, Vet Approved
MemantineMemantine may increase the bradycardic activities of Bopindolol.Approved, Investigational
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Bopindolol.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Bopindolol.Approved
MesoridazineMesoridazine may increase the hypotensive activities of Bopindolol.Approved
MetamizoleMetamizole may decrease the antihypertensive activities of Bopindolol.Withdrawn
MethacholineThe risk or severity of adverse effects can be increased when Bopindolol is combined with Methacholine.Approved
MethamphetamineMethamphetamine may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved, Illicit
Methanesulfonyl FluorideMethanesulfonyl Fluoride may increase the bradycardic activities of Bopindolol.Investigational
MethohexitalThe serum concentration of Bopindolol can be decreased when it is combined with Methohexital.Approved
MethotrimeprazineMethotrimeprazine may increase the hypotensive activities of Bopindolol.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Bopindolol.Investigational
MethylphenobarbitalThe serum concentration of Bopindolol can be decreased when it is combined with Methylphenobarbital.Approved
MidodrineBopindolol may increase the bradycardic activities of Midodrine.Approved
MilnacipranThe serum concentration of Bopindolol can be increased when it is combined with Milnacipran.Approved
MinaprineMinaprine may increase the bradycardic activities of Bopindolol.Approved
MizoribineMizoribine may decrease the antihypertensive activities of Bopindolol.Investigational
MoricizineMoricizine may increase the hypotensive activities of Bopindolol.Approved, Withdrawn
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Bopindolol.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Bopindolol.Approved
NabumetoneNabumetone may decrease the antihypertensive activities of Bopindolol.Approved
NafamostatNafamostat may decrease the antihypertensive activities of Bopindolol.Investigational
NaftifineNaftifine may decrease the antihypertensive activities of Bopindolol.Approved
NaphazolineNaphazoline may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved
NaproxenNaproxen may decrease the antihypertensive activities of Bopindolol.Approved, Vet Approved
NCX 4016NCX 4016 may decrease the antihypertensive activities of Bopindolol.Investigational
NefazodoneThe serum concentration of Bopindolol can be increased when it is combined with Nefazodone.Approved, Withdrawn
NeostigmineNeostigmine may increase the bradycardic activities of Bopindolol.Approved, Vet Approved
NepafenacNepafenac may decrease the antihypertensive activities of Bopindolol.Approved
NicotineThe risk or severity of adverse effects can be increased when Bopindolol is combined with Nicotine.Approved
Nicotine bitartrateThe risk or severity of adverse effects can be increased when Bopindolol is combined with Nicotine bitartrate.Approved
NifedipineNifedipine may increase the hypotensive activities of Bopindolol.Approved
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Bopindolol.Approved
NimesulideNimesulide may decrease the antihypertensive activities of Bopindolol.Approved, Withdrawn
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Bopindolol.Investigational
NorepinephrineBopindolol may decrease the bronchodilatory activities of Norepinephrine.Approved
OlodaterolBopindolol may decrease the bronchodilatory activities of Olodaterol.Approved
OlopatadineOlopatadine may decrease the antihypertensive activities of Bopindolol.Approved
OlsalazineOlsalazine may decrease the antihypertensive activities of Bopindolol.Approved
OrciprenalineBopindolol may decrease the bronchodilatory activities of Orciprenaline.Approved
OrgoteinOrgotein may decrease the antihypertensive activities of Bopindolol.Vet Approved
OuabainBopindolol may increase the bradycardic activities of Ouabain.Approved
OxaprozinOxaprozin may decrease the antihypertensive activities of Bopindolol.Approved
OxymetazolineOxymetazoline may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Bopindolol.Withdrawn
PaliperidonePaliperidone may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved
ParecoxibParecoxib may decrease the antihypertensive activities of Bopindolol.Approved
ParoxetineThe serum concentration of Bopindolol can be increased when it is combined with Paroxetine.Approved, Investigational
PentobarbitalThe serum concentration of Bopindolol can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PerazinePerazine may increase the hypotensive activities of Bopindolol.Investigational
PergolidePergolide may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved, Vet Approved, Withdrawn
PerphenazinePerphenazine may increase the hypotensive activities of Bopindolol.Approved
PhenobarbitalThe serum concentration of Bopindolol can be decreased when it is combined with Phenobarbital.Approved
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Bopindolol.Approved, Vet Approved
PhenylpropanolamineBopindolol may decrease the bronchodilatory activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhysostigminePhysostigmine may increase the bradycardic activities of Bopindolol.Approved
PilocarpineThe risk or severity of adverse effects can be increased when Bopindolol is combined with Pilocarpine.Approved
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Bopindolol.Approved, Investigational
PirbuterolBopindolol may decrease the bronchodilatory activities of Pirbuterol.Approved
PirfenidonePirfenidone may decrease the antihypertensive activities of Bopindolol.Investigational
PiroxicamPiroxicam may decrease the antihypertensive activities of Bopindolol.Approved, Investigational
PrazosinBopindolol may increase the orthostatic hypotensive activities of Prazosin.Approved
PrimaquineThe metabolism of Bopindolol can be decreased when combined with Primaquine.Approved
PrimidoneThe serum concentration of Bopindolol can be decreased when it is combined with Primidone.Approved, Vet Approved
ProcaterolBopindolol may decrease the bronchodilatory activities of Procaterol.Approved
ProchlorperazineProchlorperazine may increase the hypotensive activities of Bopindolol.Approved, Vet Approved
PromazinePromazine may increase the hypotensive activities of Bopindolol.Approved, Vet Approved
PromethazinePromethazine may increase the hypotensive activities of Bopindolol.Approved
PropacetamolPropacetamol may decrease the antihypertensive activities of Bopindolol.Approved
PropafenoneThe serum concentration of Bopindolol can be increased when it is combined with Propafenone.Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Bopindolol.Vet Approved
PseudoephedrinePseudoephedrine may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved
PTC299PTC299 may decrease the antihypertensive activities of Bopindolol.Investigational
PyridostigminePyridostigmine may increase the bradycardic activities of Bopindolol.Approved
RegorafenibRegorafenib may increase the bradycardic activities of Bopindolol.Approved
RemifentanilRemifentanil may increase the bradycardic activities of Bopindolol.Approved
ReserpineReserpine may increase the hypotensive activities of Bopindolol.Approved
ResveratrolResveratrol may decrease the antihypertensive activities of Bopindolol.Experimental, Investigational
RifampicinThe serum concentration of Bopindolol can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Bopindolol can be decreased when it is combined with Rifapentine.Approved
RisperidoneRisperidone may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved, Investigational
RitodrineBopindolol may decrease the bronchodilatory activities of Ritodrine.Approved
RivastigmineRivastigmine may increase the bradycardic activities of Bopindolol.Approved, Investigational
RofecoxibRofecoxib may decrease the antihypertensive activities of Bopindolol.Investigational, Withdrawn
RopiniroleRopinirole may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved, Investigational
SalbutamolBopindolol may decrease the bronchodilatory activities of Salbutamol.Approved, Vet Approved
SalicylamideSalicylamide may decrease the antihypertensive activities of Bopindolol.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Bopindolol.Approved, Vet Approved
SalmeterolBopindolol may decrease the bronchodilatory activities of Salmeterol.Approved
SalsalateSalsalate may decrease the antihypertensive activities of Bopindolol.Approved
SecobarbitalThe serum concentration of Bopindolol can be decreased when it is combined with Secobarbital.Approved, Vet Approved
SeratrodastSeratrodast may decrease the antihypertensive activities of Bopindolol.Approved, Investigational
SertralineThe serum concentration of Bopindolol can be increased when it is combined with Sertraline.Approved
SilodosinBopindolol may increase the orthostatic hypotensive activities of Silodosin.Approved
SRT501SRT501 may decrease the antihypertensive activities of Bopindolol.Investigational
SufentanilSufentanil may increase the bradycardic activities of Bopindolol.Approved, Investigational
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Bopindolol.Approved
SulindacSulindac may decrease the antihypertensive activities of Bopindolol.Approved
SuprofenSuprofen may decrease the antihypertensive activities of Bopindolol.Approved, Withdrawn
TacrineTacrine may increase the bradycardic activities of Bopindolol.Withdrawn
TamsulosinBopindolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved, Investigational
TenoxicamTenoxicam may decrease the antihypertensive activities of Bopindolol.Approved
TepoxalinTepoxalin may decrease the antihypertensive activities of Bopindolol.Vet Approved
TerazosinBopindolol may increase the orthostatic hypotensive activities of Terazosin.Approved
TerbutalineBopindolol may decrease the bronchodilatory activities of Terbutaline.Approved
TeriflunomideTeriflunomide may decrease the antihypertensive activities of Bopindolol.Approved
TheophyllineBopindolol may decrease the bronchodilatory activities of Theophylline.Approved
ThiamylalThe serum concentration of Bopindolol can be decreased when it is combined with Thiamylal.Approved, Vet Approved
ThiethylperazineThiethylperazine may increase the hypotensive activities of Bopindolol.Withdrawn
ThiopentalThe serum concentration of Bopindolol can be decreased when it is combined with Thiopental.Approved, Vet Approved
ThioridazineThioridazine may increase the hypotensive activities of Bopindolol.Approved
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Bopindolol.Approved
TinoridineTinoridine may decrease the antihypertensive activities of Bopindolol.Investigational
TizanidineTizanidine may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved
TolazamideBopindolol may increase the hypoglycemic activities of Tolazamide.Approved
TolbutamideBopindolol may increase the hypoglycemic activities of Tolbutamide.Approved
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Bopindolol.Approved
TolmetinTolmetin may decrease the antihypertensive activities of Bopindolol.Approved
TranilastTranilast may decrease the antihypertensive activities of Bopindolol.Approved, Investigational
TrichlorfonTrichlorfon may increase the bradycardic activities of Bopindolol.Vet Approved
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Bopindolol.Approved
TriflupromazineTriflupromazine may increase the hypotensive activities of Bopindolol.Approved, Vet Approved
TrimazosinBopindolol may increase the orthostatic hypotensive activities of Trimazosin.Experimental
Trisalicylate-cholineTrisalicylate-choline may decrease the antihypertensive activities of Bopindolol.Approved
TubocurarineTubocurarine may increase the bradycardic activities of Bopindolol.Approved
ValdecoxibValdecoxib may decrease the antihypertensive activities of Bopindolol.Investigational, Withdrawn
VareniclineThe risk or severity of adverse effects can be increased when Bopindolol is combined with Varenicline.Approved, Investigational
VenlafaxineThe serum concentration of Bopindolol can be increased when it is combined with Venlafaxine.Approved
VerapamilVerapamil may increase the hypotensive activities of Bopindolol.Approved
VilanterolBopindolol may decrease the bronchodilatory activities of Vilanterol.Approved
XylometazolineXylometazoline may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Bopindolol.Approved
ZileutonZileuton may decrease the antihypertensive activities of Bopindolol.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Bopindolol can be increased when it is combined with Zimelidine.Withdrawn
ZomepiracZomepirac may decrease the antihypertensive activities of Bopindolol.Withdrawn
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesC07CA17C07AA17
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (125 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.7031
Caco-2 permeable+0.5503
P-glycoprotein substrateSubstrate0.6988
P-glycoprotein inhibitor IInhibitor0.558
P-glycoprotein inhibitor IINon-inhibitor0.598
Renal organic cation transporterNon-inhibitor0.7224
CYP450 2C9 substrateNon-substrate0.8035
CYP450 2D6 substrateSubstrate0.5082
CYP450 3A4 substrateNon-substrate0.5144
CYP450 1A2 substrateInhibitor0.7481
CYP450 2C9 inhibitorNon-inhibitor0.6637
CYP450 2D6 inhibitorNon-inhibitor0.6918
CYP450 2C19 inhibitorInhibitor0.5217
CYP450 3A4 inhibitorNon-inhibitor0.5458
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.9049
Ames testNon AMES toxic0.8135
CarcinogenicityNon-carcinogens0.9013
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.7343 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9897
hERG inhibition (predictor II)Non-inhibitor0.63
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point152–153 [malonate salt]MSDS
water solubility3.3 mg/ml (malonate salt)Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0016 mg/mLALOGPS
logP4.45ALOGPS
logP4.67ChemAxon
logS-5.4ALOGPS
pKa (Strongest Acidic)16.8ChemAxon
pKa (Strongest Basic)9.29ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area63.35 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity111.07 m3·mol-1ChemAxon
Polarizability43.08 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
ClassificationNot classified

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
partial agonist
General Function:
Receptor signaling protein activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
Gene Name:
ADRB1
Uniprot ID:
P08588
Molecular Weight:
51322.1 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Joseph SS, Lynham JA, Molenaar P, Grace AA, Colledge WH, Kaumann AJ: Intrinsic sympathomimetic activity of (-)-pindolol mediated through a (-)-propranolol-resistant site of the beta1-adrenoceptor in human atrium and recombinant receptors. Naunyn Schmiedebergs Arch Pharmacol. 2003 Dec;368(6):496-503. Epub 2003 Nov 8. [PubMed:14608456 ]
  3. Doggrell SA: Effects of (+/-)- (+)- and (-)-metoprolol, (+/-)- (+)- and (-)-pindolol, (+/-)-mepindolol and (+/-)-bopindolol on the rat left atria and portal vein. Gen Pharmacol. 1991;22(6):1169-77. [PubMed:1687398 ]
  4. Berendsen HH, Broekkamp CL, Van Delft AM: Antagonism of 8-OH-DPAT-induced behaviour in rats. Eur J Pharmacol. 1990 Oct 2;187(1):97-103. [PubMed:2148726 ]
  5. Watkins DJ, Lawrence AJ, Lewis SJ, Jarrott B: Loss of [125I]-pindolol binding to beta-adrenoceptors on rat nodose ganglion after chronic isoprenaline treatment. J Auton Nerv Syst. 1996 Aug 27;60(1-2):12-6. [PubMed:8884690 ]
  6. Brodde OE, Michel MC, Wang XL, Zerkowski HR: Chronic beta-adrenoceptor antagonist treatment modulates human cardiac and vascular beta-adrenoceptor density in a subtype-selective fashion. J Hypertens Suppl. 1988 Dec;6(4):S497-500. [PubMed:2907348 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
partial agonist
General Function:
Protein homodimerization activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine.
Gene Name:
ADRB2
Uniprot ID:
P07550
Molecular Weight:
46458.32 Da
References
  1. Rubenstein LA, Zauhar RJ, Lanzara RG: Molecular dynamics of a biophysical model for beta2-adrenergic and G protein-coupled receptor activation. J Mol Graph Model. 2006 Dec;25(4):396-409. Epub 2006 Mar 30. [PubMed:16574446 ]
  2. Dejgaard A, Liggett SB, Christensen NJ, Cryer PE, Hilsted J: Adrenergic receptors are a fallible index of adrenergic denervation hypersensitivity. Scand J Clin Lab Invest. 1991 Dec;51(8):659-66. [PubMed:1666931 ]
  3. Wheeldon NM, Newnham DM, Fraser GC, McDevitt DG, Lipworth BJ: The effect of pindolol on creatine kinase is not due to beta 2-adrenoceptor partial agonist activity. Br J Clin Pharmacol. 1991 Jun;31(6):723-4. [PubMed:1678274 ]
  4. Doggrell SA: Effects of (+/-)- (+)- and (-)-metoprolol, (+/-)- (+)- and (-)-pindolol, (+/-)-mepindolol and (+/-)-bopindolol on the rat left atria and portal vein. Gen Pharmacol. 1991;22(6):1169-77. [PubMed:1687398 ]
  5. Doggrell SA: Relaxant and beta 2-adrenoceptor blocking activities of (+/- )-, (+)- and (-)-pindolol on the rat isolated aorta. J Pharm Pharmacol. 1990 Jun;42(6):444-6. [PubMed:1979630 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:
HTR1A
Uniprot ID:
P08908
Molecular Weight:
46106.335 Da
References
  1. Smeraldi E, Benedetti F, Barbini B, Campori E, Colombo C: Sustained antidepressant effect of sleep deprivation combined with pindolol in bipolar depression. A placebo-controlled trial. Neuropsychopharmacology. 1999 Apr;20(4):380-5. [PubMed:10088139 ]
  2. Haddjeri N, de Montigny C, Blier P: Modulation of the firing activity of rat serotonin and noradrenaline neurons by (+/-)pindolol. Biol Psychiatry. 1999 May 1;45(9):1163-9. [PubMed:10331108 ]
  3. Gobert A, Millan MJ: Modulation of dialysate levels of dopamine, noradrenaline, and serotonin (5-HT) in the frontal cortex of freely-moving rats by (-)-pindolol alone and in association with 5-HT reuptake inhibitors: comparative roles of beta-adrenergic, 5-HT1A, and 5-HT1B receptors. Neuropsychopharmacology. 1999 Aug;21(2):268-84. [PubMed:10432475 ]
  4. Andree B, Thorberg SO, Halldin C, Farde L: Pindolol binding to 5-HT1A receptors in the human brain confirmed with positron emission tomography. Psychopharmacology (Berl). 1999 Jun;144(3):303-5. [PubMed:10435400 ]
  5. Fornal CA, Martin FJ, Metzler CW, Jacobs BL: Pindolol suppresses serotonergic neuronal activity and does not block the inhibition of serotonergic neurons produced by 8-hydroxy-2-(di-n-propylamino)tetralin in awake cats. J Pharmacol Exp Ther. 1999 Oct;291(1):229-38. [PubMed:10490909 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances, such as lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of ...
Gene Name:
HTR1B
Uniprot ID:
P28222
Molecular Weight:
43567.535 Da
References
  1. Dawson LA, Nguyen HQ: The role of 5-HT(1A) and 5-HT(1B/1D) receptors on the modulation of acute fluoxetine-induced changes in extracellular 5-HT: the mechanism of action of (+/-)pindolol. Neuropharmacology. 2000 Apr 3;39(6):1044-52. [PubMed:10727715 ]
  2. Ariani K, Hamblin MW, Tan GL, Stratford CA, Ciaranello RD: G protein dependent alterations in [125I]iodocyanopindolol and +/- cyanopindolol binding at 5-HT1B binding sites in rat brain membranes. Neurochem Res. 1989 Sep;14(9):835-43. [PubMed:2512511 ]
  3. Leonhardt S, Herrick-Davis K, Titeler M: Detection of a novel serotonin receptor subtype (5-HT1E) in human brain: interaction with a GTP-binding protein. J Neurochem. 1989 Aug;53(2):465-71. [PubMed:2664084 ]
  4. Herrick-Davis K, Titeler M, Leonhardt S, Struble R, Price D: Serotonin 5-HT1D receptors in human prefrontal cortex and caudate: interaction with a GTP binding protein. J Neurochem. 1988 Dec;51(6):1906-12. [PubMed:3141589 ]
  5. Terron JA, Lopez-Munoz FJ, Hong E, Villalon CM: 2-(2-Aminoethyl)-quinoline (D-1997): a novel agonist at 5-hydroxytryptamine1-like receptors in the canine basilar artery. Arch Int Pharmacodyn Ther. 1994 Jan-Feb;327(1):56-68. [PubMed:7944828 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Protein homodimerization activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. Beta-3 is involved in the regulation of lipolysis and thermogenesis.
Gene Name:
ADRB3
Uniprot ID:
P13945
Molecular Weight:
43518.615 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Comments
comments powered by Disqus
Drug created on October 20, 2010 15:16 / Updated on August 17, 2016 12:24